Percutaneous nephroscopic management of upper urinary tract transitional cell carcinoma: recurrence and long-term followup

J Urol. 2004 Jul;172(1):66-9. doi: 10.1097/01.ju.0000132128.79974.db.

Abstract

Purpose: We present long-term results of the percutaneous approach and resection of upper urinary tract transitional cell carcinoma, and we evaluate the prognostic factors related to recurrence.

Materials and methods: A total of 34 patients underwent primary percutaneous resection of an upper urothelial tumor. We treated the patients with a superficial tumor that was completely resected macroscopically. Adjuvant topical chemotherapy or immunotherapy was administered. Patients were followed with excretory urography. Ureteroscopy and computerized tomography were obtained when clinically indicated.

Results: With a mean followup of 51 months ipsilateral recurrence developed in 41.2%. Median time to recurrence was 24 months. The rate of kidney preservation was 73.5%. Two patients died of the disease. There was a trend of recurrence in patients with multifocal tumors (OR 2.66, 95% CI 0.07-1.92), history of bladder carcinoma in situ (OR 2.4, 95% CI 1.61-3.74), tumor in renal pelvis (OR 6.45, 95% CI 0.01-1.46) and multiple tumor locations (OR 6.53, 95% CI 0.01-1.54).

Conclusions: The percutaneous approach to renal urothelial tumor should be considered a valid option with a good long-term outcome. Recurrence is not uncommon and, as transitional cell carcinoma superficial bladder cancer it may be treated with endourological maneuvers or radical surgery, but with the obligation to a long lasting, strict surveillance.

MeSH terms

  • Adult
  • Aged
  • Antibiotics, Antineoplastic / therapeutic use
  • Carcinoma, Transitional Cell / surgery*
  • Chemotherapy, Adjuvant
  • Endoscopy
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Mitomycin / therapeutic use
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local
  • Ureteroscopy
  • Urinary Bladder Neoplasms / surgery
  • Urologic Neoplasms / surgery*

Substances

  • Antibiotics, Antineoplastic
  • Mitomycin